Precision medicine approaches when prostate cancer Akts up

Tian Zhang; Daniel J. George; Andrew J. Armstrong

doi:10.1158/1078-0432.CCR-18-2491

Precision medicine approaches when prostate cancer Akts up

Tian Zhang, Daniel J. George, Andrew J. Armstrong

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.

Original language	English (US)
Pages (from-to)	901-903
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	3
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-2491
State	Published - Feb 1 2019
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-18-2491

Cite this

@article{23e32882b6ed47aab36d9df7e70df636,

title = "Precision medicine approaches when prostate cancer Akts up",

abstract = "Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.",

author = "Tian Zhang and George, {Daniel J.} and Armstrong, {Andrew J.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2019",

month = feb,

day = "1",

doi = "10.1158/1078-0432.CCR-18-2491",

language = "English (US)",

volume = "25",

pages = "901--903",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "3",

}

TY - JOUR

T1 - Precision medicine approaches when prostate cancer Akts up

AU - Zhang, Tian

AU - George, Daniel J.

AU - Armstrong, Andrew J.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.

AB - Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85060946531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060946531&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2491

DO - 10.1158/1078-0432.CCR-18-2491

M3 - Article

C2 - 30206162

AN - SCOPUS:85060946531

SN - 1078-0432

VL - 25

SP - 901

EP - 903

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 3

ER -

Precision medicine approaches when prostate cancer Akts up

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this